b-catenin signaling may contribute to prostate cancer (CaP) progression. Although b-catenin is known to upregulate T cell factor (TCF) target gene expression in CaP cells, recent evidence demonstrates its capacity to enhance ligand-dependent androgen receptor (AR) function. Thus, we wished to further understand the interaction between these two pathways. We find in both CaP cells (CWR22-Rv1, LAPC-4, DU145) and nonCaP cells (HEK-293, TSU, SW480, HCT-116) that bcatenin/TCF-related transcription (CRT), as measured by activation of a synthetic promoter and that of cyclin D1, is inhibited by androgen treatment. This inhibition is AR-dependent, as it only occurs in cells expressing AR endogenously or transiently, and is abrogated by AR antagonists. Additional analyses convey that the liganddependent nature of CRT suppression depends on transactivation-competent AR in the nucleus, but not on indirect effects stemming from AR target gene expression. Given the recent work identifying an AR/bcatenin interaction, and from our finding that liganded AR does not prompt gross changes in the constitutive nuclear localization of TCF4 or mutant b-catenin, we hypothesized that transcription factor (i.e. AR and TCF) competition for b-catenin recruitment may explain, in part, androgen-induced suppression of CRT. To address this idea, we expressed an AR mutant lacking its DNAbinding domain (DBD). This receptor could not orchestrate ligand-dependent CRT repression, thereby providing support for those recent data implicating the AR DBD/LBD as necessary for b-catenin interaction. Further supporting this hypothesis, TCF/LEF overexpression counteracts androgen-induced suppression of CRT, and requires b-catenin binding activity to do so. Interestingly, TCF4 over-expression potently antagonizes AR function; however, this inhibition may occur independently of b-catenin/TCF4 interaction. These results from TCF4 over-expression analyses, taken together, provide further evidence that AR-mediated suppression of CRT is a consequence of limiting amounts of b-catenin, and not AR target gene expression. Our analyses point to a reciprocal balance between AR and CRT function that may shape critical processes during normal prostate development and tumor progression.
Introduction
Prostate cancer (CaP) is the most commonly diagnosed non-cutaneous neoplasia in American men (Tindall and Scardino, 1999) . Currently, there is tremendous interest in understanding the molecular mechanisms responsible for the initiation and progression of this disease. Although more diagnoses are being made at an early stage, identification of those patients who need more aggressive therapy constitutes a major question. Hence, there is high demand for reliable molecular markers which would improve prognosis and treatment. Androgen ablation via castration and/or administration of chemical antagonists (e.g. anti-androgens) is the most common treatment for advanced CaP, although it is rarely curative . Most tumors (androgen-dependent) rapidly respond to therapy, but usually progress to the more lethal, androgen-independent form for which only experimental treatments exist.
To date, multiple gene products have been implicated in contributing to prostate tumorigenesis (Elo and Visakorpi, 2001) . Prominent among these is the androgen receptor (AR), which plays a central role in prostate cell growth and differentiation (Cude et al., 1999; Culig et al., 1998) . The AR, which is a member of the steroid receptor family of transcription factors, mediates target gene expression upon ligand binding. The primary ligand utilized by wildtype AR is dihydrotestosterone (DHT), a metabolite of testosterone, which increases AR protein half-life (MacLean et al., 1997) . Target gene expression relies on AR homodimerization at androgen-responsive elements (AREs) present in promoter sequences and formation of a strong interaction between the ligand binding domain (LBD) and amino terminal domain (NTD) . Earlier studies have shown that the NTD imparts to AR ligand-independent activation (Jenster et al., 1991; Simental et al., 1991) , whereas LBD imparts liganddependent activation of AR (Voegel et al., 1996; MacLean et al., 1997) . That unliganded AR can be found in both the cytosol and nucleus (Husmann et al., 1990; Jenster et al., 1991) implies AR target gene expression is not solely dependent on nuclear localization, but also hitherto uncharacterized nuclear events. This idea is exemplified from studies tracking GFPtagged AR in live cells showing differences in subnuclear localization upon either androgen or antiandrogen treatment (Tyagi et al., 2000; Tomura et al., 2001) . Further adding to this complexity is work demonstrating that AR bound to the anti-androgen bicalutamide associates with AREs, but remains in a transcriptionally-incompetent state (Masiello et al., 2002) .
The possible oncogenic nature of AR was suggested with the discovery that its expression is very common in tissues from patients failing hormonal-ablation therapy (i.e. androgen-independent disease) (Hobisch et al., 1995) . Further, recent work has demonstrated that AR is essential for proliferation of hormonerefractory CaP cells (Zegarra-Moro et al., 2002) . Such AR is found to exhibit altered activity; despite the ablation of androgen and its blockade, expression of markers (e.g. PSA) for measuring AR transcription is typically detectable (Cude et al., 1999) . These findings have spurred intense interest in understanding the molecular etiology of ligand-independent AR function. Mutations that lower the specificity of AR LBD have been found and demonstrated to broaden the range of agonistic ligands available for AR stimulation (Taplin et al., 1995; Tan et al., 1997; McDonald et al., 2000) . Genomic amplification of the AR locus with a correlated increase of expression has also been shown in recurrent CaP (Linja et al., 2001) . Finally, a vast array of mechanisms have been elucidated that are based on ligand-independent stimulation of AR via interactions with other signaling pathways commonly altered in cancer (Culig et al., 1994; Nazareth and Weigel, 1996; Wen et al., 2000; Yeh et al., 1999; Hobisch et al., 1998) . Conversely, ligand-dependent stimulation of AR by intersecting pathways has been reported (Truica et al., 2000; Chesire et al., 2002; Yang et al., 2002; Park et al., 2000; Lu et al., 2001) , and may play a role in prostatic tumor progression to androgenindependence.
b-catenin was originally characterized as a structural component for adherens-mediated cell/cell junctions (Takeichi, 1991) , but has more recently been implicated as an oncogenic factor in several human cancers (Morin, 1999) , including CaP (Voeller et al., 1998; Chesire et al., 2000 Chesire et al., , 2002 Gerstein et al., 2002) . Because of its potential role in tumorigenesis, much focus has been drawn to understanding the mechanisms of b-catenin signaling and regulation. b-catenin serves as an intracellular effector molecule for wnt cell/ cell signaling (Miller et al., 1999) , a developmental pathway well characterized in invertebrate models. Although the function of wnt/b-catenin signaling is not well understood in mammals, work has linked it to processes driving cell proliferation required for tissue morphogenesis (Hsu et al., 2001; DasGupta and Fuchs, 1999; Brisken et al., 2000; Huelsken et al., 2001) . The amino terminus of soluble b-catenin is subject to phosphorylation by glycogen synthase kinase-3b (GSK-3b) which, in turn, targets b-catenin to ubiquitination and proteasomal degradation (Miller et al., 1999) . Scaffolding proteins, including axin and the adenomatous polyposis coli (APC) gene product, are Figure 1 AR inhibits CRT induction of a synthetic promoter in a ligand-dependent fashion. Assays were performed in the context of CSS. (a -d) Cells were transfected with either pOT (CRT) or pBK-PSE-PB (AR Activity) reporter constructs (50 ng) plus individual expression constructs (pcDNA, Del b-cat, AR) (50 ng) as listed. (e) AR Dose Response. Cells were transfected with reporter constructs (as above) plus Del b-cat (50 ng) and AR (as listed). Total experimental DNA (i.e. AR) was brought to 50 ng with the appropriate amount of pcDNA. (a -e), After transfection (24 h), cells were exposed to various concentrations of synthetic androgen (R1881, key inset) (e, 1 nM only) or vehicle (ethanol). Luciferase assays were performed *24 h post-R1881 treatment. (e) For HEK-293 and DU145 cells, scaled-up transfection experiments were performed to demonstrate increase in AR expression as a function of dose (protein blots below graphs). Cells were plated to 24-well (HEK-293) or six-well (DU145) plates and transfected with pcDNA/ AR at 46(HEK-293) or 206(DU145) the amount used for luciferase assay. A GFP expression construct was included per well (HEK-293, 20 ng; DU145, 100 ng) to monitor transfection efficiency. R1881 exposure (1 nM) was performed (as above) for all wells. RIPA lysates (HEK-293, 25 mg; DU145, 75 mg) were resolved by 10% SDS -PAGE, transferred, and probed with anti-AR, GFP, and a-tubulin (a-tub, loading control) IgGs. nd, not determined required for this targeting process. One arm of the wnt pathway serves to downregulate GSK-3b function, thus increasing b-catenin protein half-life. Consequent bcatenin accrual leads to its nuclear accumulation and interaction with the TCF/LEF family of DNA binding proteins. In doing so, b-catenin relieves the transcriptional repressor function of TCF by displacing corepressors and recruiting co-activators, thus transactivating gene expression Cavallo et al., 1998) . In this report, we refer to b-catenin/TCFdriven gene expression as CRT . To date, several target genes of CRT have been described, including proto-oncogenes myc, jun, and cyclin D1 (He et al., 1998; Mann et al., 1999; Tetsu and McCormick, 1999) . Importantly, target genes have been found that orchestrate negative-feedback on b-catenin signaling (Roose et al., 1999; Spiegelman et al., 2000; Hovanes et al., 2001; Lustig et al., 2002; Jho et al., 2002; Yan et al., 2001; Leung et al., 2002) .
Besides the degradation of b-catenin induced by GSK-3b phosphorylation, additional regulatory processes have been uncovered that potentially modulate CRT. Evidence exists demonstrating a role for p53 signaling in initiating b-catenin degradation independent of GSK-3b activity (Liu et al., 2001; Matsuzawa and Reed, 2001) . Architectural components of the cell such as E-cadherin and caveolin-1 may impinge on CRT by sequestering soluble b-catenin to the membrane (Sadot et al., 1998; Galbiati et al., 2000) . Inside the nucleus, CRT is subject to diverse regulation, ranging from competition for b-catenin by transcription factors besides TCF (Zorn et al., 1999) to modification of TCF (Ishitani et al., 1999; Sachdev et al., 2001) . Several undiscovered levels of CRT regulation likely exist and may only become apparent when examined under different temporal and tissuespecific contexts.
With respect to tumorigenesis, aberrantly high bcatenin signaling can result from either direct mutation in its degradation targeting domain or from alterations in its regulators Korinek et al., 1997; Rubinfeld et al., 1997; Satoh et al., 2000; Liu et al., 2000) . Little is known regarding the function of bcatenin signaling in normal and neoplastic prostate physiology. b-catenin mutations have been documented in CaP (*5%) and are associated with increased bcatenin nuclear localization in vivo and CRT in vitro (Voeller et al., 1998; Chesire et al., 2000) . Although these mutations occur almost exclusively in primary disease, the discovery of b-catenin nuclear localization in *20% of metastatic cases who had failed androgen ablation therapy suggests a more prominent role for CRT in CaP progression (Chesire et al., 2002) . Along with evidence of b-catenin mutation occurring early in colorectal cancer (Samowitz et al., 1999) , these data correlate well with recent work finding that mutations in b-catenin or its regulators (APC, b-TRCP) stratify separately to either primary or metastatic disease, respectively (Gerstein et al., 2002) . Although it was not possible in the latter study to address the genetic status in those primary tumors that gave rise to the mutation-positive secondary lesions, a dichotomy in the molecular etiology underlying putative b-catenin activation is consistent among these studies, and may reflect different selective pressures that propagate certain subsets of CaP.
The diverse role of AR in CaP progression, and potentially that of b-catenin, predicts that these two pathways interact. Indeed, b-catenin has been shown to augment AR transcriptional function in a liganddependent fashion (Truica et al., 2000; Chesire et al., 2002; Yang et al., 2002) . Further, yeast two-hybrid experiments have shown that AR interacts with bcatenin and may shuttle b-catenin to the nucleus (Mulholland et al., 2002; Pawlowski et al., 2002; Yang et al., 2002) . These findings, along with data demonstrating b-catenin interaction with other steroid receptor family members (Easwaran et al., 1999; Palmer et al., 2001) , stimulated our interest in determining the consequences of AR activity on that of b-catenin/TCF target gene expression. Such effects on CRT, if any, should be considered when ascertaining the contribution of b-catenin to both normal and neoplastic prostate physiology.
Results

Ligand-dependent inhibition of b-catenin/TCF gene expression (CRT) by AR
The observation of b-catenin-mediated augmentation of ligand-dependent AR activity (Truica et al., 2000; Chesire et al., 2002) , together with data demonstrating a direct AR/b-catenin interaction (Mulholland et al., 2002; Yang et al., 2002) , suggests that components of each pathway may be further subject to crossregulation. Previous work shows that steroid receptors can recruit nuclear co-factors utilized by other pathways, potentially affecting the performance of the latter (Yanagisawa et al., 1999; Song et al., 1999) . With respect to androgen signaling, AR can modulate transcription executed by other factors such as AP-1 and SMAD proteins (Aarnisalo et al., 1998; Chipuk et al., 2002) . Therefore, we were provoked to examine the effect of androgen signaling on CRT.
By luciferase assay, we measured AR transcriptional activity using a heterologous AR reporter containing the human prostate-specific antigen enhancer (Schuur et al., 1996) coupled to the minimal rat probasin promoter (pBK-PSE-PB) (Rennie et al., 1993) , and CRT using a synthetic b-catenin/TCF-dependent reporter termed pOT (Chesire et al., 2002) . To induce CRT, we over-expressed a constitutively active form of b-catenin (Del b-cat) containing an interstitial deletion originally identified in a patient with hormonerefractory disease. This deletion (D24 -47), which encompasses the entire GSK-3b phosphorylation domain, does not encroach on the armadillo repeats (residues 140 -671) which mediate several of bcatenin's interactions (Chesire et al., 2000) . Consistent with previous work , CRT induction was dependent on the three TCF-binding elements of pOT, as the same reporter containing mutated TCF-binding elements (pOF) showed abrogated activity (data not shown). Whereas both ARpositive cell lines CWR22-Rv1 and LAPC-4 exhibited AR activity upon treatment with synthetic androgen R1881 ( Figure 1a , AR Activity), we only observed androgen-induced suppression of CRT in the former (Figure 1a , CRT). AR is required for this CRT suppression, as AR-negative cells (DU145, TSU, HEK-293) only display androgen-dependent CRT reduction upon ectopic AR expression (Figure 1b , CRT). Interestingly, AR over-expression in LAPC-4 cells similarly resulted in the ability to down-modulate CRT given the presence of androgen (Figure 1c, CRT) . Throughout these experiments, we noted that androgen-induced suppression of CRT did not necessarily correlate with elevated AR transcriptional activity (Figure 1b, , at least when considered using this particular AR reporter. Affirming these observations, AR doseresponse assays demonstrated that CRT decreases mainly as a function of the total amount of liganded AR and not its transcriptional output (Figure 1e , HEK-293 and DU145, bar graphs and gel panels). In this particular experiment, the drop in AR transcription with higher AR doses (25 and 50 ng) in HEK-293 and DU145 likely results from a squelching effect. In a predetermined squelching experiment, over-expression of AR (50 ng) in CWR22-Rv1 cells slightly dampened AR transcription readout (Figure 1d , AR Activity); however, ligand-dependent CRT interference was much more pronounced (Figure 1d , CRT). Altogether, these data imply that liganded (i.e. transcriptionally-competent) AR may commandeer a factor(s) required for optimal CRT induction in prostate cells. The inability of LAPC-4 cells to manifest this phenomenon ( Figure  1a ) could be due to an intrinsic quality of this cell line as it relates to androgen signaling, or to the parameters of our assay (e.g. stimulation time). As expected from previous work (Chesire et al., 2002) , LAPC-4 cells displayed lower AR functional capacity compared to CWR22-Rv1 (Figure 1a , AR Activity). Under our experimental conditions, this disparity would not be predicted to result from CWR22-Rv1 cell expression of mutant AR (LBD, H874Y; see Tan et al., 1997) , in comparison to wildtype receptor expression by LAPC-4 cells (Klein et al., 1997) . Although ectopic AR prompted robust AR transcriptional activity in LAPC-4 cells (Figure 1c , AR Activity), our data ( Figure 1d ,e) imply that the concomitant manifestation of ligand-dependent CRT repression is not a direct consequence of the former event.
In several circumstances, a ligand-independent decrease in CRT occurred with AR over-expression (e.g. Figure 1d , CWR22-Rv1; Figure 1e , LAPC-4). Generally speaking, such was the case in certain experiments with LAPC-4 and HEK-293 cells. The ligand-independent component of CRT suppression by AR could originate from its recruitment of CBP/p300, which possibly proceeds under androgen-free conditions (Fronsdal et al., 1998; Aarnisalo et al., 1998) .
Since CBP/p300 may contribute to b-catenin-mediated transactivation of TCF (Takemaru and Moon, 2000; Hecht et al., 1999; Sun et al., 2000) , it is possible that CBP capture by AR produces poor CRT. Although of interest, we are unable to speculate on the nature of the ligand-independent escalation of CRT induction upon ectopic AR expression in AR-negative cells (Figure 1b, TSU and DU145; Figure 1e, DU145) .
Our studies have utilized cells that are not known to exhibit intrinsically high levels of CRT, both CaPderived (CWR22-Rv1, LAPC-4, DU145) and non-CaPderived (HEK-293, TSU) (Chesire et al., 2002) . Here, it is important to note that recent work with the TSU cell line, which was previously believed to be of prostatic origin, has established its derivation from a bladder cell line (van Bokhoven et al., 2001) . To extend our findings, we questioned if androgenic signaling could modulate CRT in cells that display inherently high levels thereof. The colon cancer cells, SW480 and HCT-116, bear loss of APC and activating b-catenin mutations, respectively, that potentiate constitutively elevated CRT Korinek et al., 1997) . R1881 treatment of these cells following transient AR expression prompted moderate inhibition of intrinsic CRT (Figure 2 ). This observation further suggests that CRT interference by AR is not dependent on cell type-specific factors.
The pOT reporter is very useful for assessing CRT activity in cells, but may not yield signaling profiles mirroring that which occurs with natural target gene promoters. Thus, we performed similar analyses with the cyclin D1 promoter which can be regulated by the b-catenin/TCF bipartite transcription complex (Tetsu and McCormick, 1999) In HEK-293 cells, the transcriptional co-activators, CBP and p300, may be of limited availability due to expression of the adenovirus CBP/p300-interacting protein E1A (Arany et al., 1995) . We therefore speculate, as above, that such ligand-independent suppression may ensue from an increase in AR interaction with CBP/p300 (Fronsdal et al., 1998; Aarnisalo et al., 1998) , thus impinging on CRT (Takemaru and Moon, 2000; Hecht et al., 1999; Sun et al., 2000) . An alternative explanation exists which is premised on the finding of a Creb-binding element in the cyclin D1 promoter that may be necessary for optimal magnitude, but not induction, of CRT (Tetsu and McCormick, 1999) . Perhaps the latter hypothesis is more likely, since CRT measured with the synthetic reporter (pOT) does not manifest a substantial ligandindependent decrease (Figure 1b, e; . Taken together, these results confirm those provided in Figure  1 , and give credibility to the notion that androgen signaling may inhibit expression of endogenous CRT target genes. However, we regard this data with some caution, as factors other than b-catenin/TCF (e.g. those upregulated by CRT) may provide the basis for induction of cyclin D1 promoter by b-catenin overexpression. Although work to determine the specificity of this ligand-dependent diminution in CRT is ongoing, we posit that it is specific, as deletion studies Figure  2b ,c) imply that certain androgen-regulated processes require cyclin D1 downregulation. This proposition is not unreasonable given the role of androgen signaling in promoting not only cellular proliferation, but also differentiation and proliferative shutoff (Sonnenschein et al., 1989) . Lastly, this phenomenon may represent a counter-regulation by AR against one of its corepressors, cyclin D1 (Knudsen et al., 1999; Petre et al., 2002) .
Anti-androgens alleviate androgen-induced CRT repression by AR
We wished to determine whether or not chemical inhibition of AR would impact CRT suppression induced by androgen signaling. Two competitive inhibitors were utilized; cyproterone acetate, a mixed agonist/antagonist, and Casodex (bicalutamide), a pure antagonist. During our study, we were in a position to rapidly test the effects of mutant b-catenin expression on AR activity under androgen-ablative conditions. Micromolar concentrations of cyproterone acetate were required to block AR transcription in CWR22-Rv1 cells (Figure 4a, +pcDNA) . Under the conditions of our assay, cyproterone acetate did not demonstrate agonism towards AR. Despite co-activation by Del bcat expression, AR activity was similarly inhibited by cyproterone acetate (Figure 4a , +Del b-cat). DU145 cells were used as an AR-negative control (Figure 4a,  DU145) . In an identical study with Casodex (data not shown), 10 mM concentration was required to block AR induction by 1 nM R1881. In the context of Del bcat expression, Casodex inhibition of enhanced AR activity was marginally alleviated. These results are consistent with the current working hypothesis that bcatenin co-stimulates AR in manner dependent on Figure 5 Relief of ligand-dependent CRT suppression by anti-androgens may be recapitulated in AR-negative cells. All assays were performed in a CSS context. Experiments were performed similarly as those in Figure 1b , although only CRT (pOT reporter) was measured Figure 6 Nuclear localization of TCF4 and mutant b-catenin is not grossly altered by androgen exposure and does not affect AR localization. Upon culture in RPMI/10% CSS (24 h), CWR22-Rv1 cells were transiently transfected with Del b-cat (a) or TCF4 (b) expression contructs (0.5 mg) for 24 h and then exposed to R1881 (1 nM) for 24 h. Fixed cells were co-stained with rabbit anti-AR IgG plus either mouse anti-b-catenin IgG (a) or mouse anti-TCF4 IgG (b), followed by anti-rabbit IgG-Alexa 488 and anti-mouse IgG-rhodamine. DNA was stained with DAPI. With these camera acquisition settings, b-catenin cell/cell border staining is not pronounced (a) nor is weak endogenous TCF4 staining visible (b). Generally, AR staining was much weaker than that of b-catenin and ectopic TCF4. To demonstrate specificity of the Alexa 488 signal (i.e. no rhodamine bleedthrough), cells were stained with only mouse primary IgGs, but with both secondary IgGs (e.g. a, right-hand cropped images). Images were acquired at 4006magnification ligand (i.e. agonist). Indeed, the b-catenin/AR interaction discovered by yeast two-hybrid experiments required DHT, and AR-mediated nuclear import of b-catenin was blocked with AR antagonists (Yang et al., 2002; Pawlowski et al., 2002) .
We found that cyproterone acetate-mediated blockade of AR transcriptional activity (Figure 4b , AR Activity) was inversely related to CRT suppression by R1881 treatment in CWR22-Rv1 cells (Figure 4b , CRT). DU145 cells were used as an AR-negative control (Figure 4b, DU145 ). This data indicates that the mechanism of CRT blockade may require ligand binding. Potentially, agonist stimulation establishes AR as transcriptionally-competent, capable of recruiting nuclear co-factors such as b-catenin. In confirmation of the cyproterone acetate effects on CRT, addition of Casodex (10 mM) to CWR22-Rv1 cells relieved androgen-mediated suppression of CRT at the same concentration required for AR blockade (Figure 4c , CWR22-Rv1). However, Casodex did not affect CRT in AR-negative cells (Figure 4c , HEK-293). The reproducibility of these data were tested with the cyclin D1 promoter (71009 bp). In similar fashion to readout from the synthetic CRT reporter, cyproterone acetate (10 mM) prevented the reduction of CRT by R1881 in CWR22-Rv1 cells (Figure 4e ).
An attempt to recapitulate the rescue of CRT via AR antagonism in AR-negative cells produced confounding results. Both cyproterone acetate (10 mM) and Casodex (10 mM) elicited ligand-independent downregulation of CRT in cells transiently expressing AR ( Figure 5 , DU145 and HEK-293, fifth and sixth column groups). With DU145 cells, it is conceivable that this reduction reflects a nullification of the little understood androgen-independent stimulation of CRT (Figures 1b,e and 3c) ; however, this logic cannot be applied to deciphering the androgenindependent CRT drop in HEK-293 cells ( Figure 5 , HEK-293, fifth and sixth column groups). This drop in reporter readout could represent the non-specific effects, though less in magnitude, elicited by both anti-androgens in the absence of AR ( Figure 5 , HEK-293, second and third column groups). Given this caveat, it is fair to reason that cyproterone acetate did prohibit ligand-dependent CRT repression in both cell lines, as CRT remained stable despite androgen challenge ( Figure 5 , fifth column groups). Interestingly, Casodex only alleviated CRT suppression against R1881 concentrations of 0.1 and 1 nM, but not 10 nM, suggesting that high androgen concentrations overcome this form of AR antagonism ( Figure 5 , sixth column groups).
We wished to determine firsthand the effects of these anti-androgens on AR localization. Any substantial alteration in such may explain, in part, how chemical inhibition of AR relieves its suppression of CRT. Following previous work, CWR22-Rv1 cells treated with R1881 (1 nM) demonstrated pronounced nuclear AR staining compared to more diffuse staining in the untreated control (Figure 4d ) (Chesire et al., 2002) . Anti-androgens alone induced intense nuclear AR in CWR22-Rv1 and LAPC-4 cells which was not significantly altered by R1881 co-treatment ( Figure  4d , data not shown). These observations are consistent with recent work which include tracking GFP-tagged AR movement in live cells under multiple conditions (Tyagi et al., 2000; Tomura et al., 2001; Masiello et al., 2002) . Our immunofluorescence (IF) analysis utilized fixed cells and did not exploit the sensitivity benefits of confocal microscopy, perhaps explaining how these results differ from those reported (Tyagi et al., 2000; Tomura et al., 2001 ) insofar as subnuclear AR localization is concerned. That said, these data imply that AR-mediated suppression of CRT does not simply rely on nuclear presence of AR, but rather the molecular state of AR in the nucleus (i.e. transcriptional competence). For example, AR antagonists may permit its association with co-repressors (Dotzlaw et al., 2002; Shang et al., 2000) , thus barring recruitment of factors required for CRT.
Repression of CRT by androgen signaling is not associated with an alteration in TCF4 or mutant b-catenin (Del b-cat) nuclear localization
We undertook to determine if the two major components of CRT, b-catenin and TCF, are altered in their localization pattern upon androgen stimulation. Regardless of androgen exposure, large changes in their expression levels have not been detected (data not shown). Although simplistic in theory, changes in localization of either of these molecules could give insight into the mechanism of CRT suppression. Indeed, the determinants that govern nuclear localization of activated b-catenin are not completely understood; however, work has implicated TCFs and APC in this process (Huber et al., 1996; Henderson, 2000; Rosin-Arbesfeld et al., 2000) . Transiently expressed Del b-cat in CWR22-Rv1 cells accumulated in the nucleus as expected (Chesire et al., 2002) , and such was not altered by androgen status (Figure 6a , bcatenin). At this level of sensitivity, AR localization (1 nM R1881) and intensity was not noticeably affected by nuclear b-catenin. Although the parameters of this experiment do not conform perfectly to those of two recent studies (Mulholland et al., 2002; Pawlowski et al., 2002) , this result is consistent with their conclusion of a role for AR in nuclear import of b-catenin.
Most CaP cell lines in culture express TCF4, but little or none of the three other TCF/LEF transcription factor family members (LEF, TCF1, TCF3; unpublished data). Therefore, we examined TCF4 localization as a function of androgen treatment in CWR22-Rv1 cells. Over-expressed TCF4 displayed nuclear staining that was not appreciably altered with R1881 exposure (Figure 6b, TCF4) . Altogether, we conclude from this IF study that CRT repression by AR does not involve drastic changes in b-catenin and TCF localization.
Correlation of androgen-dependent repression of CRT with AR/b-catenin interaction
We wished to probe in greater molecular detail, the nature of this form of CRT repression. Our data (Figure 4d ) points to the inhibitory effect occurring in the nucleus. CBP/p300 over-expression analyses in CWR22-Rv1 cells demonstrated no evidence for their putative role in AR's ability to induce CRT suppression (unpublished data). This outcome corresponds well with alternative ligand-independent CBP/p300 binding by AR (Aarnisalo et al., 1998; Fronsdal et al., 1998) , which lies in contradiction to the requirement of androgen in CRT modification. In several cases, co-factors tend to bind to AR in a liganddependent fashion do so through the LBD (MacLean et al., 1997), thereby predicting that b-catenin may coactivate AR by such means. Therefore, CRT modulation may occur via a restriction imposed by liganded AR on TCF access to b-catenin transactivation. This idea has precedent with the finding that LBD is necessary for AR to implement inhibition of TGF-b signaling via SMAD-3 recruitment, albeit in a ligandindependent fashion (Chipuk et al., 2002) . Given these considerations, we constructed an AR D-DBD (D538 -614) expression construct (Figure 7a) to test whether or not such a mutant, which is anticipated to display limited target gene expression, would be able to suppress CRT. This question was centered on the idea that such a mutant AR would retain its capacity to associate with b-catenin, presumably through its LBD, thereby incurring CRT inhibition in a manner independent of AR target gene transcription. During preparation of this manuscript, however, reports on AR/b-catenin complex formation were published demonstrating that either AR LBD alone (Yang et al., 2002) , or both LBD and DBD (Mulholland et al., 2002) , are requisite for complex formation. Given the findings of Mulholland et al. (2002) , we were not entirely surprised in observing that cells (HEK-293, DU145) transiently transfected with AR (D538 -614) did not manifest ligand-dependent interference of CRT (Figure 7b, CRT) . As expected, this mutant construct exhibited abrogated AR target gene expression ( Figure  7b , AR Activity; data not shown). Close inspection of this data reveals that, despite comparable increases in induction of reporter activity by wildtype AR (1 nM R1881) and D538 -614 AR (10 nM R1881, presum ARindependent), only the former greatly reduces CRT (Figure 7b , HEK-293). This finding is consistent with the notion that AR target gene expression is not requisite for ligand-driven decrease in CRT. Based on these results, in conjunction with the probability that AR (D538 -614) may not complex with b-catenin (Mulholland et al., 2002) , we infer that liganded AR may prohibit CRT through depriving TCF of b-catenin co-stimulation. Work to determine if AR (D538 -614) has impaired b-catenin-binding activity is underway.
If b-catenin is sought after by both TCF and liganded AR, the balance between these two transcription factors may influence the outcome of nuclear bcatenin signaling. Analogous studies of nuclear factor cross-regulation have demonstrated that such phenomena can be reciprocal in nature (Chipuk et al., 2002; Palmer et al., 2001; Fronsdal et al., 1998) . Thus, we examined the effects of TCF4, and two mutants thereof (Figure 8a ), on the equilibrium between AR and CRT signaling. Corresponding with previous work (Miller et al., 1999) , we confirmed that TCF4 mutants lacking a complete b-catenin binding domain (DN and DN-DHMG) fail to interact with b-catenin in IP analysis ( Figure 8b) ; however, these mutants exhibit the same nuclear localization as that of wildtype protein ( Figure  8c ). Androgen-dependent CRT suppression was abolished with over-expression of wildtype TCF4 in CWR22-Rv1 cells (Figure 8e , full length). To digress, the absence of synergy between TCF4 and mutant bcatenin in driving CRT is related to the experimental conditions in Figure 8e (see figure legend), as they do synergize in a fetal calf serum (FCS) media context (Figure 8d, full length) . We next probed the requirement of b-catenin-binding activity by TCF4 on its mitigation of CRT repression. Use of DN TCF4 yielded results difficult to interpret due to its strong dominant-negative action on CRT (Figure 8d,e; DN) . Therefore, we introduced a second deletion in DN TCF4 removing its HMG DNA binding domain. Overexpression of this mutant prompted much less inhibition of CRT and likely manifests another, more modest, dominant-negative behavior (Figure 8d , DN-DHMG; unpublished data). Importantly, this TCF4 construct was unable to prohibit ligand-dependent repression of CRT (Figure 8e , DN-DHMG), implying that TCF4 competes with AR for b-catenin. Thus, the pivotal factor underlying ligand-dependent inhibition of CRT by AR could be b-catenin. This outcome with wildtype TCF4 over-expression (Figure 8e, full length) may represent a general property of all TCF/LEF family members, as ectopic expression of LEF1 likewise mollifies the effects of androgen signaling on CRT (Figure 8f) . Noticeably, LEF1 synergized with mutant b-catenin to potentiate CRT. were transfected into CWR22-Rv1 cells in six-well plate format. Forty-eight hours post-transfection, cells were lysed in NP40 detergent buffer and sheared. Pre-cleared lysates (200 mg total protein in 600 ml) were subject to IP (48C, 4 h) with 2 mg/ml mouse anti-TCF4 or anti-b-galactosidase (cont) IgGs, followed by pulldown with protein A/G-coupled agarose (48C, 1 h). IPs were resolved by 6% SDS -PAGE, transferred, and probed with the appropriate antibodies. Endogenous TCF4, though faint, is apparent with longer film exposure to blot. Note that, unlike full length TCF4, both DN TCF4 expression products do not interact with b-catenin. cont, control. (c) CWR22-Rv1 cells were transfected with the appropriate TCF4 construct (0.5 mg). Forty-eight hours post-transfection, cells were fixed and stained with mouse anti-TCF4 IgG (a-TCF4) followed by anti-mouse IgG-rhodamine. DNA was stained with DAPI. Immunofluorescence images were acquired under 4006magnification. Note that all three TCF4 expression products display nuclear localization. (d) Under FCS culture conditions, CWR22-Rv1 cells were transfected with the CRT reporter pOT plus the appropriate expression construct combinations, as listed. Twenty-four hours post-transfection, luciferase assays were performed. (e,f) Assays were performed in a CSS context. As in c, cells were appropriately transfected. Post-transfection treatments and luciferase assays were as in Figure 1 . The effects of TCF4 construct (e) and wildtype LEF1 (f) expression on R1881-induced CRT suppression were determined TCF4 over-expression inhibits AR transcriptional activity in a manner independent of b-catenin binding Data garnered in our work with anti-androgens (Figures 4 and 5 ) might suggest that the protective effects of wildtype TCF/LEF on CRT (Figure 8 ) derive from their own negative effects on AR function. To assess this possibility, we performed assays to evaluate the effects of TCF4 constructs on AR transcription. Over-expression of all three constructs in CWR22-Rv1 cells blocked AR activation of the pBK-PSE-PB reporter (Figure 9a) . Similar results were obtained in experiments that included co-expression of mutant bcatenin (data not shown). To demonstrate that the prohibitive effect of TCF4 on AR function is not inherent to CWR22-Rv1 cells alone, the constructs were also shown to block R1881-induced activity of the same reporter in LAPC-4 and DU145 cells (Figure 9b , data not shown). TCF4 antagonism of AR target gene expression may not be promoter specific, as the ARresponsive promoter/enhancer of human kallikrein-2 (HK2) (Yu et al., 1999) was also subject to inhibition, though more pronounced (Figure 9c ). Importantly, both TCF4 mutants defective in b-catenin binding (DN, DN-DHMG) displayed the same level of AR inhibition as wildtype TCF4 (Figure 9a -c) . Therefore, we conclude that the counter-regulation of ARmediated transcription by TCF4 may not involve decreased b-catenin access by the former. As our data (i.e. DN-DHMG TCF4 expression) suggests, TCF4 likely does not interrupt AR transcription in the same mode as another HMG-containing transcription factor, Figure 9 TCF4 inhibits androgen signaling in a manner independent of b-catenin binding. All experiments were performed in a CSS context. (a -c) AR transcription reporter plus the appropriate expression vector were transfected into cells followed by androgen treatment and luciferase assays as in Figure 1 . Similar results were obtained in experiments that included mutant b-catenin expression (data not shown). (a) As in Figure 1e , pcDNA was used to equalize total transfected DNA, as appropriate. Either CWR22-Rv1 (a,c) or LAPC-4 (b) cells were tested. pBK-PSE-PB (a,b) or pBK-HK2-promoter/enhancer (c) androgen-responsive reporters were utilized SRY, which antagonizes AR via the HMG domain (Yuan et al., 2001) . Much work is necessary to determine the nature of this AR inhibition, though initial findings imply that such inhibition is not a result of any obvious changes in AR localization (Figure 6b,  AR) .
Use of the DN-DHMG TCF4 mutant has advanced our understanding of the mechanism of androgeninduced CRT repression. Although this mutant cannot block CRT suppression (Figure 8e, DN-DHMG) , it does block AR activity (Figure 9, DN-DHMG) , aptly supporting our previous data (Figure 1d,e) demonstrating that CRT suppression may not be a consequence of AR target gene expression, but rather competition for nuclear co-factors (e.g. b-catenin).
Discussion
A major push to understand the regulation of CRT has yielded much insight into the interactions of nuclear b-catenin. Such interest has largely been fostered by evidence that this pathway likely plays an important role in both tissue development (e.g. wnt signaling) and oncogenesis. Our interest to further understand the regulation and consequence of CRT in prostate cells ensued mainly from observations of bcatenin mutation and nuclear localization in clinical CaP specimens (Chesire et al., 2000; . Several groups have recently reported b-catenin/AR complex formation (Yang et al., 2002; Pawlowski et al., 2002; Mulholland et al., 2002) , potentially resulting in an augmentation of AR transcriptional function in a ligand-dependent manner. Such data provided a rationale for our motivation to ascertain the reciprocity, if any, between CRT and androgen signaling. Here, we have demonstrated that a balance may exist, as manifested by CRT inhibition by AR in a liganddependent fashion. This downregulation of CRT may result from b-catenin recruitment by transcriptionallycompetent AR, thereby lessening the level of TCF transactivation. Furthermore, TCF4 can inhibit AR activity in a manner distinct from TCF4/b-catenin interaction.
A recent experiment performed by Pawlowski et al. (2002) supports our conclusion that androgen signaling may impart negative-feedback on CRT. Furthermore, they demonstrated that TCF over-expression potentially dampens AR transcriptional function. Overall, these transcriptional events are likely not dependent on any particular cellular context, as we have shown their occurrence using various reporter constructs in multiple cell lines. Fundamentally, these activities may only rely on the interplay of the aforementioned nuclear factors as a function of ligand milieu. We are led to this conclusion based on previous work (mapping of AR/b-catenin interaction site, see Mulholland et al., 2002) and our efforts showing that, (i) CRT obstruction by androgen signaling is relieved by TCF4 competent in b-catenin binding, (ii) Liganded AR with putative b-catenin-binding dysfunction does not impinge on CRT, (iii) Chemically antagonized AR does not impinge on CRT in the presence of androgen, and (iv) TCF4 inhibits AR function regardless of bcatenin binding. Ongoing work aims to confirm and further elucidate these points.
Besides AR, b-catenin has been shown to interact with two other members of the steroid receptor family, vitamin D receptor (VDR) (Palmer et al., 2001 ) and retinoic acid receptor (RAR) (Easwaran et al., 1999) , in a manner driven by ligand. In addition to observing an interaction, both these studies (Palmer et al., 2001; Easwaran et al., 1999) documented enhancement of steroid receptor transcriptional output with b-catenin co-stimulation by ligand-dependent means. Certain aspects of our report are analogous to their findings, especially those documenting a decrease in CRT coincident with ligand treatment. Taken together, these discoveries accentuate the notion that commonalities undergird the mechanisms of steroid receptor and bcatenin signaling cross-regulation. Important differences do exist, however, with our report and that of Palmer et al. (2001) . Although they correlated CRT interference with E-cadherin expression upon vitamin D-induced cell differentiation, they also linked this repression to VDR/b-catenin complex formation. Thus, vitamin D signaling may consequently block CRT through two sequential events; that mediated by VDR recruitment of b-catenin, and then via b-catenin sequestration to cell/cell junctions. The latter could lead to a dampening in VDR activity as well, hence forming a negative-feedback loop. With androgen stimulation, we never observed any morphological changes, nor did we see upregulation of proteins previously implicated in CRT suppression (Sadot et al., 1998; Galbiati et al., 2000) (caveolin-1, E-cadherin; data not shown). Conversely, our analyses suggest that androgen-dependent CRT inhibition is mediated through the direct means of competitive b-catenin binding by transcriptionally-competent AR, although we cannot discount effects that may ensue with longer periods of androgen exposure.
On another note, Palmer et al. (2001) noted inhibition of VDR transcriptional activity upon overexpression of wildtype TCF4, but not DN TCF4, demonstrating that b-catenin may be the candidate cofactor under dual regulation by TCF and VDR. Likewise, AR transcriptional activity was hindered by wildtype TCF4 over-expression; however, this inhibition may not entirely reside in depriving AR access to b-catenin, as DN TCF4 constructs orchestrated the same effects. We determined that a DN TCF4 protein defective in DNA binding (DN-DHMG) greatly relieves the dominant-negative effects of the former on CRT. Therefore, we conjecture that this b-catenin-independent mode (i.e. use of DN TCF4 constructs) of AR antagonism may not derive from either perturbation of CRT target gene expression (e.g. loss of CRTdependent expression of an AR co-factor) or negative trans-acting events within AR-targeted promoters (i.e. DNA-binding and interaction with AR transcriptional complex). Regarding the effects of b-catenin/steroid receptor complex formation on CRT, it is possible that the b-catenin/VDR interaction is more dominant than that of b-catenin and AR. Signaling analyses show that TCF4-mediated inhibition of VDR is totally eliminated upon mutant b-catenin expression (Palmer et al., 2001 ). This finding is in contrast to our unpublished results, and those of Pawlowski et al. (2002) , showing that TCF4, when co-expressed with mutant b-catenin, continues to negatively impact AR transcriptional function. Furthermore, wildtype TCF4 over-expression does not avert CRT diminution by liganded VDR, whereas we observe that such over-expression yields CRT recalcitrant to the inhibitory effects of liganded AR. On the other hand, these discrepancies may partly be accounted for by the differentiation effects elicited by vitamin D. All in all, these various distinctions between our report and that of Palmer et al. (2001) may highlight features unique to each of these steroid receptor signaling pathways, especially regarding those interactions with the b-catenin pathway.
We have previously shown that b-catenin signaling may be associated with processes driving prostate gland growth (Chesire et al., 2002) . This inference is based on observing nuclear b-catenin in rat prostate epithelium concomitant with testosterone-induced regrowth of atrophic glands. This phenomenon may be explained by recent data documenting ligand dependent nuclear import of b-catenin by AR (Pawlowski et al., 2002; Mulholland et al., 2002) . Reports have implicated wnt signaling in aspects of tissue morphogenesis that rely heavily on steroidal inputs (Gavin and McMahon, 1992; Weber-Hall et al., 1994; Brisken et al., 2000; Vainio et al., 1999) . Given these precedents, it is plausible that wnt factors, acting downstream of androgen signaling, stimulate b-catenin nuclear localization and CRT during prostate regrowth. Indeed, the heterogeneous staining for nuclear b-catenin (i.e. positive and negative nuclei) in that experiment (Chesire et al., 2002) is compatible with the hypothesis proposed by Lustig et al. (2002) that such staining may result from CRT-mediated expression of axin-2 (conductin), prompting b-catenin downregulation. b-catenin signaling may act to promote tissue morphogenesis (Hsu et al., 2001; DasGupta and Fuchs, 1999) . Thus, if certain mechanistic processes involved in both prostate development and testosterone-induced gland restoration are shared (e.g. cell proliferation/death), then b-catenin signaling (CRT) may play a role in the former. Under these circumstances, b-catenin may act to augment AR signaling. In turn, as gland development approaches completion, CRT-stimulated growth (and/or cell death, for that matter) may subside as a consequence of androgen-mediated repression of b-catenin. In this model, albeit very hypothetical, cross-regulation exerted between CRT and AR signaling would contribute to formation of a gland with normal morphogenic properties (e.g. morphometry). In addition to its potential impact on prostate development, we conjecture that AR/b-catenin cross-regulation may influence the selection and progression of CaP lesions bearing aberrantly high levels of CRT; therefore, further studies in this area are warranted.
Our conclusions, and those from related reports (Palmer et al., 2001; Easwaran et al., 1999; Pawlowski et al., 2002) , are based on analyses performed in vitro. As is necessary with these kinds of studies, much effort will be devoted to understand their respective relevance in vivo. This notion similarly applies to those studies of ligand-dependent b-catenin co-stimulation of AR (Chesire et al., 2002; Truica et al., 2000; Yang et al., 2002) . Currently, only correlative evidence for bcatenin's direct role in CaP exists with the discovery of its mutation and putative activation therein (Chesire et al., 2000 (Chesire et al., , 2002 Gerstein et al., 2002; Voeller et al., 1998) . Hopefully, transgenic models will become available soon to better understand the function of nuclear b-catenin in prostate. At this time, we can only speculate on how the interplay between b-catenin and AR signaling pathways affects prostate physiology, both normal and pathologic.
Materials and methods
Cells lines, chemicals, plasmids and antibodies
Cells were acquired from the American Type Culture Collection (Manassas, VA, USA; DU145, SW480, HCT-116, HEK-293) and Dr John Isaacs (Johns Hopkins University; TSU, CWR22-Rv1, LAPC-4). The CaP cell line CWR22-Rv1 expresses AR mutated in the LBD (Tan et al., 1997) , whereas LAPC-4 expresses wildtype AR (Klein et al., 1997) . DU145 are AR-negative CaP cells, whereas TSU, which was previously believed to originate from CaP, is a bladder cell line (van Bokhoven et al., 2001 ). SW480 and HCT-116 are colon cancer cells bearing constitutive CRT Korinek et al., 1997) . All cells were maintained at 378C/5% CO 2 in RPMI (CWR22-Rv1, DU145, TSU), DMEM (HEK-293), Iscove's Modified DMEM/1 nM R1881 (LAPC-4), or McCoy's 5A Medium (SW480, HCT-116) supplemented with 10% FCS. All media were purchased from Life Technologies (Grand Island, NY, USA). The synthetic androgen, methyltrienolone (R1881) was purchased from New England Nuclear (Boston, MA, USA). The anti-androgen cyproterone acetate was purchased from Sigma (St. Louis, MO, USA). Casodex (bicalutamide) was a gift from AstraZeneca (London, UK). Luciferin and coelenterazine (dual luciferase assay substrates) were purchased from Biosynth AG (Staad, Switzerland). For all R1881 treatment procedures, cells were incubated in media containing 10% charcoal-stripped FCS (CSS, Cocalico Biologicals, Reamstown, PA, USA) for 48 h prior to addition of the same media (fresh) including R1881.
Control plasmids pGL3-Basic (pGL3) and pRL-CMV were from Promega (Madison, WI, USA), and utilized for both luciferase assay optimization and normalization. Empty pcDNA 3.1(7) (herein referred to as pcDNA) was purchased from InVitrogen (Carlsbad, CA, USA) and used to compensate for unequal DNA/CMV promoter levels in transfection/luciferase assays. pEGFP-C1 was obtained from Clontech (Palo Alto, CA, USA) and used for tracking transfection efficiency in certain experiments (Figure 1e , gel panels). The wildtype b-catenin (herein referred to as WT bcat), wildtype TCF4 (full length), and DN TCF4 expression vectors, plus the synthetic b-catenin/TCF (CRT) reporter constructs (pOT, pOF) were provided by Dr Ken Kinzler (Johns Hopkins University). pOT consists of three optimal TCF binding sites upstream a basic promoter (TATA box) that drives firefly luciferase expression. As described in a previous report (Chesire et al., 2002) , AR activity was measured with the luciferase reporter constructs pBK-PSE-PB and pBK-HK2-enhancer/promoter (provided by Dr Ron Rodriguez, Johns Hopkins University). pBK-PSE-PB consists of the human prostate-specific antigen enhancer (PSE; 1592 bp BamHI/BglII fragment from the CN-65 construct, see Schuur et al., 1996) fused to the rat probasin promoter (PB; bp 7421 to +42 of sequence reported by Rennie et al., 1993) . This reporter permits efficient AR-driven activity, as it contains four AREs, two in the PSE and two in the PB. The human kallikrein-2 (HK2) enhancer/promoter construct contains the regulatory sequences from the CP390 androgen-sensitive reporter (see Yu et al., 1999) . The cyclin D1 reporter (pGL3-Cyclin D1) contains 1009 bp of the cyclin D1 5'-proximal region (bp 1058?2067 of GenBank sequence, accession L09054). Using genomic DNA, PCR with Pfu polymerase (Stratagene, La Jolla, CA, USA) was performed to amplify the appropriate fragment which was subsequently cloned using the pTOPO Blunt kit (InVitrogen). The promoter was then subcloned through the use of primerintroduced restriction sites (BglII, HindIII) into pGL3. pCIDel-b-catenin (herein referred to as Del b-cat) was used for expression of a mutant form (D24 -47) of b-catenin that lacks the GSK-3b phosphorylation target sites and exhibits constitutive nuclear activity (Chesire et al., 2000) . Use of another Del b-cat expression construct (pcDNA 3.1-Del-bcatenin) demonstrated the same activity as pCI-Del-b-cat (data not shown). A recombinant PCR approach was taken to construct TCF4 expression vectors lacking the high mobility group (HMG) DNA binding domain (bp 1286 -1493, D327 -395; see GenBank accession Y11306 for reference). Although this study only utilized DN-DHMG TCF4, DHMG TCF4 was also developed and assayed (data not shown). Briefly, Pfu polymerase was used to amplify two fragments (A, 5' relative to HMG; B, 3' relative to HMG) from the original TCF4 expression vectors with the use of vector-specific and coding primers. The 3' end of fragment A contained sequence through bp/1285 and including bp 1493 -1501. The 5' end of fragment B contained bp 1267 -1285 continuing to bp 1493?. Fragments A and B were purified and entered into a second Pfu amplification reaction using only the two vector-specific primers. Recombinant product was cloned into its original vector and sequenced. In construction of the LEF1 vector, Pfu amplification of LEF1 ORF from LAPC-4 cDNA was performed. The LEF1 ORF was cloned with the pTOPO Blunt reaction kit and then inserted into pcDNA (XbaI, HindIII). Sequence analysis identified the LEF1 clone as that in the GenBank database (accession B39625). pcDNA-hAR (herein referred to as AR) was used for expression of wildtype human AR (Chesire et al., 2002) . Recombinant PCR was used to develop AR lacking the DBD (D538 -614). Similar as above, two fragments (A and B) were Pfu-amplified. Fragment A 3' end contained sequence through bp/2725 and including bp 2957 -2965 (see accession NM_000044 for reference). Fragment B 5' end contained bp 2718 -2725 continuing to bp 2957?. As above, a recombinant fragment was Pfuamplified, sequenced, and placed into pcDNA (XbaI, XhoI).
Antibodies were obtained from Transduction Laboratories (Lexington, KY, USA; b-catenin), Pharmingen (San Diego, CA, USA; mouse anti-AR mAb, see Figures 1e, 4d and 7a), Affinity BioReagents (Golden, CO, USA; rabbit anti-AR pAb, see Figure 6a ,b), Calbiochem (La Jolla, CA, USA; atubulin, b-galactosidase), Upstate Biotechnology (Lake Placid, NY, USA; TCF4), Torrey Pines BioLabs (San Diego, CA, USA; GFP), Jackson ImmunoResearch Laboratories (West Grove, PA, USA; rhodamine-conjugated donkey antimouse IgG), Molecular Probes (Eugene, OR, USA; Alexa Fluor 488-conjugated donkey anti-rabbit IgG), and Pierce (Rockford, IL, USA; horseradish peroxidase-conjugated goat anti-mouse and anti-rabbit IgG).
Immunocytochemistry
Immunocytochemistry was performed essentially as reported (Chesire et al., 2000) . Primary antibodies (PBS/3.75% BSA) were incubated with fixed and permeabilized cells on two chamber glass slides (Nunc, Naperville, IL, USA) at 1 : 250 (bcatenin), 1 : 100 (AR, mouse mAb and rabbit pAB), and 2 mg/ ml (TCF4) dilutions. As appropriate, slides were then treated with rhodamine-conjugated anti-mouse IgG (1 : 400) and/or Alexa Fluor 488-conjugated anti-rabbit IgG (1 : 2000), washed, mounted with Prolong Antifade (Molecular Probes), and viewed under fluorescence microscopy (AxioScope, Carl Zeiss, Thornwood, NY, USA). Images were documented using IPLab image-capturing software. Non-specific background was monitored by treating specimens with secondary antibody only.
Immunoprecipitation and Western blot analyses
Cell lysates were prepared from subconfluent cultures by first washing cells twice with cold PBS and then extracting with either RIPA (50 mM Tris 7.4, 0.5% DOC, 0.2% SDS, 1.0 NP-40, 150 mM NaCl, 1 mM EDTA) or NP40 (50 mM Tris 7.4, 1.0% NP40, 150 mM NaCl, 1 mM EDTA) detergent buffer solutions. Protein concentrations of lysates were determined using a BCA assay (Pierce). All cell lysates and immunoprecipitation (IP) mixes contained a protease inhibitor cocktail (Roche, Indianapolis, IN, USA). Parameters for TCF4 IP analysis are listed in Figure 8b legend. G+/A agarose beads were acquired from Oncogene Research Products (Cambridge, MA, USA). Prior to gel loading, SDS -PAGE gel loading buffer (Sambrook et al., 1989) was added to the beads and heated at 958C for 4 min.
Techniques for running SDS -PAGE and Western blots were as described (Sambrook et al., 1989) . Pre-stained molecular weight standards were purchased from Bio-Rad (Hercules, CA, USA). Upon completion of electrophoresis, proteins were transferred by Western blot to ECL nitrocellulose (Amersham-Pharmacia, Piscataway, NJ, USA) and blocked in 5% non fat-dried milk/PBS/0.1% Tween-20. Membranes were probed in blocking buffer with antibodies, washed, and probed with HRP-conjugated secondary antibody (anti-IgG). For appropriate blots, a-tubulin levels were also determined to verify equal loading. Enhanced chemiluminescence was performed with the ECL kit (AmershamPharmacia) followed by autoradiography.
Transfection and luciferase assays
Luciferase assay experiments were performed essentially as described (Chesire et al., 2002) . Cells were plated at medium density to clear bottom, opaque-walled 96 well plates (Isoplate TC, Perkin Elmer Wallac, Gaithersburg, MD, USA). With those experiments involving androgen treatment, cells were given media/10% CSS 24 h after plating (day 2), transfected (day 3), treated with R1881 (and anti-androgen as appropriate, day 4), and analysed for luciferase activity (day 5). For those experiments performed in an FCS context, transfections were carried out on day 2. Transfections were performed using Fugene 6 Transfection Reagent (Roche) at 1 mL/0.2 mg DNA. To compensate for unequal DNA/CMV promoter levels between certain transfection groups, pcDNA was included as appropriate. pRL-CMV (10 ng), which encodes Renilla luciferase, was included in all mixes. For non-luciferase assay transfections, important parameters are listed in the appropriate figure legends.
Luciferase assays were performed as described using nonproprietary substrate/buffer mixes (Dyer et al., 2000) . Cells were washed once in PBS and lysed in 30 ml 16Passive Lysis buffer (Promega). Using the Wallac 1450 Microbeta Jet luminescence reader, firefly and Renilla luciferase substrate mixes (100 ml) were injected sequentially, allowing 10 s readout for each enzyme. All experiments were repeated at least three times, and all experimental groups therein were performed in replicates of six. To control for transfection efficiency for individual wells, firefly luciferase values were normalized to the corresponding Renilla values. Regarding measurement of CRT with the pOT reporter, use of the pOF control vector demonstrated little or no background associated with pOT activity (i.e. TCF-independent activity, data not shown), therefore normalized pOT-generated luciferase values are reported directly.
